✦ LIBER ✦

Novel Therapies for the Control and Prevention of Neuropathic Pain

✍ Scribed by Christine N. Sang; Gary J. Bennett

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 6
Category: Article
ISSN: 1933-7213
DOI: 10.1016/j.nurt.2009.08.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluoxetine for the treatment of neuropat

Fluoxetine for the treatment of neuropathic pain

✍ Abdula, A ;Burden, A C 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Ca2+ Channel α2-δ Ligands for the Treatm

Ca2+ Channel α2-δ Ligands for the Treatment of Neuropathic Pain.

✍ Mark J. Field; Zheng Li; Jacob B. Schwarz 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 11 KB

The Engineering of an Orally Active Cono

The Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain

✍ Richard J. Clark; Jonas Jensen; Simon T. Nevin; Brid P. Callaghan; David J. Adam 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 1 views

The Engineering of an Orally Active Cono

The Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain

✍ Richard J. Clark; Jonas Jensen; Simon T. Nevin; Brid P. Callaghan; David J. Adam 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 514 KB

Prospects for Metabotropic Glutamate 1 R

Prospects for Metabotropic Glutamate 1 Receptor Antagonists in the Treatment of Neuropathic Pain.

✍ Jeffrey M. Schkeryantz; Ann E. Kingston; Michael P. Johnson 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 11 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

Neuronal nicotinic acetylcholine recepto

Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain

✍ Michael D. Meyer 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 1 views

## Abstract Neuronal nicotinic acetylcholine receptor (nAChR) agonists have been demonstrated to exhibit antinociceptive, antihyperalgesic, and antiallodynic effects across a range of preclinical models of pain. Yet, to date, no drugs have been successfully developed and approved for the treatment